Targeting Engineered Nanoparticles for Breast Cancer Therapy

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2021 Nov 27

PMID 34834243

Citations 19

Authors

Kumar Ganesan

Yan Wang

Fei Gao

Qingqing Liu

Chen Zhang

Peng Li

Jinming Zhang

Jianping Chen

Affiliations

Soon will be listed here.

Abstract

Breast cancer (BC) is the second most common cancer in women globally after lung cancer. Presently, the most important approach for BC treatment consists of surgery, followed by radiotherapy and chemotherapy. The latter therapeutic methods are often unsuccessful in the treatment of BC because of their various side effects and the damage incurred to healthy tissues and organs. Currently, numerous nanoparticles (NPs) have been identified and synthesized to selectively target BC cells without causing any impairments to the adjacent normal tissues or organs. Based on an exploratory study, this comprehensive review aims to provide information on engineered NPs and their payloads as promising tools in the treatment of BC. Therapeutic drugs or natural bioactive compounds generally incorporate engineered NPs of ideal sizes and shapes to enhance their solubility, circulatory half-life, and biodistribution, while reducing their side effects and immunogenicity. Furthermore, ligands such as peptides, antibodies, and nucleic acids on the surface of NPs precisely target BC cells. Studies on the synthesis of engineered NPs and their impact on BC were obtained from PubMed, Science Direct, and Google Scholar. This review provides insights on the importance of engineered NPs and their methodology for validation as a next-generation platform with preventive and therapeutic effects against BC.

Citing Articles

Nanomaterials in gastric cancer: pioneering precision medicine for diagnosis, therapy, and prevention.

Liu T, Gu Y, Zhao Y, Li Y Med Oncol. 2025; 42(4):93.

PMID: 40050498 DOI: 10.1007/s12032-025-02650-3.

Cetuximab-conjugated sodium selenite nanoparticles for doxorubicin targeted delivery against MCF-7 breast cancer cells.

Moni S, Abdelwahab S, Mohan S, Riadi Y, Elmobark M, Areshyi R Nanomedicine (Lond). 2024; 19(29):2447-2462.

PMID: 39381998 PMC: 11520552. DOI: 10.1080/17435889.2024.2403962.

Platinum Group Metals Nanoparticles in Breast Cancer Therapy.

Alven S, Gandidzanwa S, Ngalo B, Poswayo O, Madanhire T, Aderibigbe B Pharmaceutics. 2024; 16(9).

PMID: 39339199 PMC: 11434984. DOI: 10.3390/pharmaceutics16091162.

Recent Advances on Pt-Based Compounds for Theranostic Applications.

Ferrari G, Lopez-Martinez I, Wanek T, Kuntner C, Montagner D Molecules. 2024; 29(15).

PMID: 39124859 PMC: 11313463. DOI: 10.3390/molecules29153453.

Advancements in nanomaterials for nanosensors: a comprehensive review.

Darwish M, Abd-Elaziem W, Elsheikh A, Zayed A Nanoscale Adv. 2024; 6(16):4015-4046.

PMID: 39114135 PMC: 11304082. DOI: 10.1039/d4na00214h.

References

de Jong W, Borm P . Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine. 2008; 3(2):133-49. PMC: 2527668. DOI: 10.2147/ijn.s596. View

Huang Y, Cambre M, Lee H . The Toxicity of Nanoparticles Depends on Multiple Molecular and Physicochemical Mechanisms. Int J Mol Sci. 2017; 18(12). PMC: 5751303. DOI: 10.3390/ijms18122702. View

Chawla S, Chua V, Fernandez L, Quon D, Blackwelder W, Gordon E . Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer. Mol Ther. 2009; 18(2):435-41. PMC: 2839309. DOI: 10.1038/mt.2009.228. View

Oliveira M, Saura C, Nuciforo P, Calvo I, Andersen J, Passos-Coelho J . FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. Ann Oncol. 2019; 30(8):1289-1297. DOI: 10.1093/annonc/mdz177. View

Zhang J, Zhang W, An C, Li X, Ma L . Comparative research on Tc-Rituximab and Tc-sulfur colloid in sentinel lymph node imaging of breast cancer. BMC Cancer. 2019; 19(1):956. PMC: 6794795. DOI: 10.1186/s12885-019-6197-9. View

Bhagwat G, Athawale R, Gude R, Md S, Alhakamy N, Fahmy U . Formulation and Development of Transferrin Targeted Solid Lipid Nanoparticles for Breast Cancer Therapy. Front Pharmacol. 2020; 11:614290. PMC: 7729133. DOI: 10.3389/fphar.2020.614290. View

Jahangirian H, Kalantari K, Izadiyan Z, Rafiee-Moghaddam R, Shameli K, Webster T . A review of small molecules and drug delivery applications using gold and iron nanoparticles. Int J Nanomedicine. 2019; 14:1633-1657. PMC: 6417854. DOI: 10.2147/IJN.S184723. View

Ardavanis A, Mavroudis D, Kalbakis K, Malamos N, Syrigos K, Vamvakas L . Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study. Cancer Chemother Pharmacol. 2006; 58(6):742-8. DOI: 10.1007/s00280-006-0236-3. View

Chen Z . Small-molecule delivery by nanoparticles for anticancer therapy. Trends Mol Med. 2010; 16(12):594-602. PMC: 3729441. DOI: 10.1016/j.molmed.2010.08.001. View

10.

Tang H, Zhang H, Ye H, Zheng Y . Receptor-Mediated Endocytosis of Nanoparticles: Roles of Shapes, Orientations, and Rotations of Nanoparticles. J Phys Chem B. 2017; 122(1):171-180. DOI: 10.1021/acs.jpcb.7b09619. View

11.

Salkho N, Paul V, Kawak P, Vitor R, Martins A, Al Sayah M . Ultrasonically controlled estrone-modified liposomes for estrogen-positive breast cancer therapy. Artif Cells Nanomed Biotechnol. 2018; 46(sup2):462-472. DOI: 10.1080/21691401.2018.1459634. View

12.

Martin-Romano P, Baraibar I, Espinos J, Legaspi J, Lopez-Picazo J, Aramendia J . Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience. Breast J. 2017; 24(4):473-479. DOI: 10.1111/tbj.12975. View

13.

Rizvi S, Saleh A . Applications of nanoparticle systems in drug delivery technology. Saudi Pharm J. 2018; 26(1):64-70. PMC: 5783816. DOI: 10.1016/j.jsps.2017.10.012. View

14.

Li N, Wang X, Lin B, Zhu H, Liu C, Xu X . Clinical Evaluation of 99mTc-Rituximab for Sentinel Lymph Node Mapping in Breast Cancer Patients. J Nucl Med. 2016; 57(8):1214-20. DOI: 10.2967/jnumed.115.160572. View

15.

Yang F, Hsu N, Moi S, Lu Y, Hsieh C, Chang K . Efficacy and toxicity of pegylated liposomal doxorubicin-based chemotherapy in early-stage breast cancer: a multicenter retrospective case-control study. Asia Pac J Clin Oncol. 2017; 14(3):198-203. DOI: 10.1111/ajco.12771. View

16.

Peer D, Karp J, Hong S, Farokhzad O, Margalit R, Langer R . Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2008; 2(12):751-60. DOI: 10.1038/nnano.2007.387. View

17.

Du C, Qi Y, Zhang Y, Wang Y, Zhao X, Min H . Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 ( BRCA2) Mutation. ACS Nano. 2018; 12(11):10785-10796. DOI: 10.1021/acsnano.8b01573. View

18.

Blum J, Savin M, Edelman G, Pippen J, Robert N, Geister B . Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer. 2008; 7(11):850-6. DOI: 10.3816/CBC.2007.n.049. View

19.

Matsuda N, Wang X, Lim B, Krishnamurthy S, Alvarez R, Willey J . Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncol. 2018; 4(9):1207-1213. PMC: 6143003. DOI: 10.1001/jamaoncol.2018.1436. View

20.

Lobo C, Lopes G, Baez O, Castrellon A, Ferrell A, Higgins C . Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 2010; 123(2):427-35. DOI: 10.1007/s10549-010-1002-0. View